PV Bulletin
PvBulletin

Tag archive

AI

AI/GxPFdaUnited States

FDA posts January 2025 draft Level 1 guidance on AI use

Relevant for
QPPVRegulatory Intelligence LeadPV Quality LeadVendor Oversight Lead+1 more
Action needed

1) Inventory AI use cases that could feed regulated decisions (including PV/safety-related analyses or summaries used in regulatory interactions) and map owners/vendors. 2) For each AI use case, document context of use, intended outputs, and controls (e.g., review/approval, traceability, change management) aligned to a draft-guidance tracking plan. 3) Track the Federal Register notice and plan whether to submit comments within the window described by FDA (90 days after Federal Register publication).

Process impact
Vendor OversightInspection ReadinessAI / GxP Governance
SOP impact

4 SOPs may need review

Urgency: HighConfidence: medium
Read impact brief
Company Watch

BMS to deploy Anthropic’s Claude across drug development workflows

Relevant for
QPPVSignal Management LeadLabeling LeadRegulatory Intelligence Lead+3 more
Action needed

This update requires triage for Signal Validation, Vendor Oversight, Inspection Readiness; confirm local obligations and document follow-up actions.

Process impact
Signal ValidationVendor OversightInspection Readiness
SOP impact

8 SOPs may need review

Urgency: HighConfidence: medium
Read impact brief

Get updates for your PV role

Subscribe to receive impact-first pharmacovigilance updates tailored by role and workflow.

Current context: role PV Technology / CSV Lead, workflow Vendor Oversight.